- Home
- CLX
as of 03-17-2026 3:39pm EST
$111.82
$0.27
-0.24%
Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.
| Founded: | 1913 | Country: | United States |
| Employees: | N/A | City: | OAKLAND |
| Market Cap: | 14.9B | IPO Year: | 1994 |
| Target Price: | $121.08 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 1.93 | EPS Growth: | 189.78 |
| 52 Week Low/High: | $96.66 - $150.84 | Next Earning Date: | 05-04-2026 |
| Revenue: | $6,124,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -7.56% | Revenue Growth (next year): | 7.64% |
| P/E Ratio: | 58.13 | Index: | |
| Free Cash Flow: | 761.0M | FCF Growth: | +11.94% |
AI-Powered CLX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.47%
75.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 3, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 3, 2026 · 100% conf.
AI Prediction SELL
1D
-3.19%
$111.31
Act: +2.43%
5D
-4.46%
$109.86
Act: +5.63%
20D
-5.43%
$108.74
Act: +2.13%
Price: $114.98 Prob +5D: 0% AUC: 1.000
0000021076-26-000008
clx-202602030000021076False00000210762026-02-032026-02-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
Delaware1-0715131-0595760 (State or other jurisdiction of(Commission File Number)(I.R.S. Employer incorporation)Identification No.)
1221 Broadway, Oakland, California 94612-1888 (Address of principal executive offices) (Zip code) (510) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock - $1.00 par value
CLX New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition On February 3, 2026, The Clorox Company issued a press release announcing its financial results for its second quarter ended December 31, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure Attached hereto as Exhibit 99.2 and incorporated herein by reference is supplemental financial information. Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below.
EXHIBIT INDEX
Exhibit Description 99.1Press Release dated February 3, 2026 of The Clorox Company
99.2Supplemental information regarding financial results
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CLOROX COMPANY
Date: February 3, 2026 By:/s/ Angela Hilt Angela Hilt Executive Vice President – Chief Legal and External Affairs Officer & Corporate Secretary
3
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0000021076-25-000051
clx-202511030000021076False00000210762025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
Delaware1-0715131-0595760 (State or other jurisdiction of(Commission File Number)(I.R.S. Employer incorporation)Identification No.)
1221 Broadway, Oakland, California 94612-1888 (Address of principal executive offices) (Zip code) (510) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock - $1.00 par value
CLX New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition On November 3, 2025, The Clorox Company issued a press release announcing its financial results for its first quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure Attached hereto as Exhibit 99.2 and incorporated herein by reference is supplemental financial information. Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below.
EXHIBIT INDEX
Exhibit Description 99.1Press Release dated November 3, 2025 of The Clorox Company
99.2Supplemental information regarding financial results
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CLOROX COMPANY
Date: November 3, 2025 By:/s/ Angela Hilt Angela Hilt Executive Vice President – Chief Legal and External Affairs Officer & Corporate Secretary
3
2025 Q2 Q2 2025 Earnings
8-K Jul 31, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 31, 2025
0000021076-25-000035
clx-202507310000021076False00000210762025-07-312025-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
Delaware1-0715131-0595760 (State or other jurisdiction of(Commission File Number)(I.R.S. Employer incorporation)Identification No.)
1221 Broadway, Oakland, California 94612-1888 (Address of principal executive offices) (Zip code) (510) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
[ ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock - $1.00 par value
CLX New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition On July 31, 2025, The Clorox Company issued a press release announcing its financial results for its fourth quarter and fiscal year ended June 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure Attached hereto as Exhibit 99.2 and incorporated herein by reference is supplemental financial information. Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below.
EXHIBIT INDEX
Exhibit Description 99.1 Press Release dated July 31, 2025 of The Clorox Company
99.2 Supplemental information regarding financial results
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE CLOROX COMPANY
Date: July 31, 2025By:/s/ Angela Hilt Angela Hilt Executive Vice President – Chief Legal and External Affairs Officer and Corporate Secretary
3
Latest Clorox Company (The) News
CLX Breaking Stock News: Dive into CLX Ticker-Specific Updates for Smart Investing
Simply Wall St.
Clorox (CLX) Valuation Check After Mixed Recent Share Price Performance
➖
AI Sentiment
Neutral
5/10
Simply Wall St.
Hidden Valley Ranch Europe Push Tests Clorox Brand Relevance Strategy
➖
AI Sentiment
Neutral
5/10
Compare CLX vs Leading Stocks
See how CLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CLX Clorox Company (The) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.